Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kunamin in COVID-19 Patients
NCT05417997Phase 3Completed
- Sponsor
- RAAS Nutritionals
- Start
- May 2021
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by RAAS Nutritionals. Primary endpoints: Decrease in COVID-19, cold and flu viral load at 15 days, Produce COVID-19 antibodies at 30 days and 4 more. Started May 2021; status: completed.
Beyond the preview
Go deeper on NCT05417997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417997.